Item

CONCORDE: A Multicentre Phase Ib Trial of DNA Damage Response Inhibitors and Durvalumab Consolidation in Patients with Unresectable Stage IIB/III NSCLC Undergoing Radiotherapy: The Newcastle experience

Greystoke, A.
; 
Hassani, A.
; 
Philip, R.
; 
Pickles, R.
; 
Smith, E.
; 
Turnbull, H.
; 
Willis, N.
; 
Stamp, A.
; 
Sellars, S.
; 
Kendall, J.
... show 10 more
Citations
Google Scholar:
Lookup
Altmetric:
Abstract
Authors
Greystoke, A.
Hassani, A.
Philip, R.
Pickles, R.
Smith, E.
Turnbull, H.
Willis, N.
Stamp, A.
Sellars, S.
Kendall, J.
Oughton, J.
Brown, S.
Walker, F.
Franks, K.
Harrow, S.
Shaw, P.
Walls, G.
Hiley, C.
Ojo, O.
Rizos, K.
Chalmers, A.
Faivre-Finn, C.
Affiliation
Newcastle Tyne Hosp NHS Fdn Trust, Northern Ctr Canc Care, Newcastle Upon Tyne, England Newcastle Univ, Ctr Canc, Newcastle Upon Tyne, England Leeds Inst Clin Trials Res, Canc Res UK Clin Trials Unit, Leeds, England Univ Leeds, Leeds Teaching Hosp NHS Trust, Leeds, England Western Gen Hosp, Edinburgh Canc Ctr, Edinburgh, Scotland Velindre Univ NHS Trust, Cardiff, Wales Univ Manchester, Christie NHS Fdn Trust, Manchester, England Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Belfast, North Ireland UCL Canc Inst, Dept Oncol, London, England AstraZeneca, Cambridge, England Mt Vernon Canc Ctr, Natl Radiotherapy Trials Qual Assurance Grp, Northwood, England Univ Glasgow, Inst Canc Sci, Glasgow, Scotland
Description
Date
2025
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Greystoke A, Hassani A, Philip R, Pickles R, Smith E, Turnbull H, et al. CONCORDE: A Multicentre Phase Ib Trial of DNA Damage Response Inhibitors and Durvalumab Consolidation in Patients with Unresectable Stage IIB/III NSCLC Undergoing Radiotherapy: The Newcastle experience. Lung cancer (Amsterdam, Netherlands). 2025 FEB;200. PubMed PMID: WOS:001445247500012. English.
Journal Title
Journal ISSN
Volume Title
URI
https://christie.openrepository.com/handle/10541/627607
Embedded videos